Tezspire (tezepelumab), from AstraZeneca and Amgen, has succeeded in a Phase 3 trial for eosinophilic esophagitis (EoE) — positioning it to compete with Sanofi’s Dupixent.
What eosinophilic esophagitis is
EoE is a chronic immune condition in which eosinophils — white blood cells associated with allergic responses — accumulate in the lining of the esophagus, driving inflammation.
It is best understood as an allergic disease of the esophagus, typically triggered by food proteins. Patients experience difficulty swallowing, food impaction and chest pain, and many adapt without realising it: eating slowly, cutting food very small, drinking constantly with meals, avoiding textures like bread and steak. Some arrive at diagnosis only after food becomes physically stuck and requires endoscopic removal.
Untreated, chronic inflammation drives fibrosis — the esophagus scars and narrows, and that structural damage does not fully reverse. Treating early therefore matters.
The trial
The CROSSING trial enrolled 368 patients aged 12–80, randomised to high-dose Tezspire, low-dose, or placebo. It met both primary and secondary endpoints — measured by esophageal eosinophil counts and a patient-reported swallowing-difficulty score. Results at one year were “statistically significant and clinically meaningful,” though specific figures were not disclosed.
Why hitting both endpoints is the whole story
This is the detail that distinguishes a real result from a technical one, and EoE drug development has repeatedly foundered on it.
Eosinophil count is the histologic measure — how many of these cells appear in a biopsy. It is objective and easy to move: several agents have dramatically reduced eosinophil counts.
The problem is that patients have frequently felt no better. Clearing eosinophils does not automatically restore swallowing, partly because symptoms in established disease reflect fibrosis and narrowing that inflammation control does not reverse, and partly because eosinophils may be a marker of the process rather than the sole cause of symptoms.
Regulators consequently expect both a histologic and a symptomatic endpoint. Meeting both is the meaningful achievement here — and the reason specific undisclosed figures matter less than the fact that both were hit.
How Tezspire works
Tezspire blocks TSLP, a signalling protein released by epithelial cells lining airways and other barrier surfaces when they encounter irritants or allergens.
TSLP sits upstream of the inflammatory cascade — among the first signals released, triggering the downstream responses that produce disease. Most biologics for allergic conditions target individual downstream cytokines; blocking an upstream alarm signal interrupts multiple downstream pathways simultaneously.
That breadth is the strategic argument, and “epithelial science represents an important and rapidly evolving area,” said AstraZeneca’s Sharon Barr — reflecting a push to address several inflammatory diseases with one antibody.
The Dupixent question
Sanofi’s Dupixent is currently the only FDA-approved biologic for EoE. Tezspire’s trial compared against placebo, not head-to-head.
That leaves the comparison unresolved, and cross-trial comparisons are unreliable — patient populations, endpoints and disease severity differ between programmes.
One analyst noted Tezspire has shown greater efficacy than Dupixent in chronic rhinosinusitis with nasal polyps, a hint of competitive potential. That is suggestive rather than probative: performing better in one allergic condition does not guarantee it in another with different tissue and mechanics.
The commercial logic
An approval would be Tezspire’s third indication — after severe asthma and, more recently, nasal polyps — with blockbuster potential. EoE affects about 470,000 people in the US.
Accumulating indications for one antibody is efficient in a way that developing separate drugs is not. Manufacturing scales across all uses, the safety database grows with every indication, and prescribers already familiar with the drug in asthma need less persuading in a new one.
It also reflects a real biological insight: if several allergic diseases share an upstream driver, a drug targeting it should work across them.
What is still unknown
The undisclosed figures are a genuine gap. “Statistically significant and clinically meaningful” is company language, and the magnitude of symptom improvement is what determines whether patients notice a difference.
Why EoE diagnoses have risen so sharply
Eosinophilic esophagitis was barely described three decades ago and is now a common gastroenterology diagnosis, and the reasons are contested in an informative way.
Part is undoubtedly recognition. The condition was not in the differential for physicians who had never heard of it, and patients presenting with difficulty swallowing were investigated for reflux or motility disorders. As awareness spread and biopsy during endoscopy became routine rather than selective, cases that had always existed began to be counted.
But most researchers think recognition alone does not account for the scale of the increase. EoE tracks with the broader rise in allergic disease across industrialised countries — asthma, eczema, food allergy — and patients frequently have several. The explanations proposed for that wider trend, involving changes in early-life microbial exposure, diet and barrier function, are the same ones invoked here.
Which matters commercially as well as scientifically: a genuinely growing patient population supports a very different market projection from a stable one being better identified.
Whether Tezspire prevents or reverses fibrotic narrowing over years is also unaddressed by a one-year trial — and for a chronic disease whose worst outcome is structural, that is the question that ultimately matters. Clinical and business news, not medical advice.